Our Recommendations
New Publications
- Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination (2022)
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- Manual del Vacunador Vacuna MODERNA para uso pediátrico de 6 a 11 años Campaña Nacional de Vacunación contra la COVID-19 (2022)
- Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022 (2022)
- WHO Science in 5 Episode #78 - mRNA technologies (2022)
Filter
132
Featured
Recommendations
24
New Publications
59
Language
Document type
Guidelines
44
Fact sheets
43
Studies & Reports
14
Resource Platforms
11
Manuals
7
Infographics
5
Situation Updates
4
Videos
3
Training Material
1
Countries / Regions
Germany
16
Brazil
8
Russia
8
West and Central Africa
6
East and Southern Africa
6
Argentina
6
India
6
Mozambique
3
Africa
3
Latin America and the Carribbean
2
Middle East and North Africa
2
Western and Central Europe
2
South Sudan
2
Turkey
1
Kazakhstan
1
Global
1
Haiti
1
Guinea-Bissau
1
France
1
United Kingdom
1
Portugal
1
Spain
1
South Korea
1
Belarus
1
Vietnam
1
Angola
1
Authors & Publishers
Publication Years
Category
COVID-19
52
Guidelines
11
Information, Education and Communication (IEC)
7
Studies & Reports
4
x MEDBOX Issue Brief & Annual Reports x
2
Women & Child Health
2
Countries
1
Policies
1
Immunization
1
Toolboxes
Vaxzevria (Astra Zeneca)
26
Research & Pipeline
26
Biontech/Pfizer Comirnaty
23
Inactivated COVID-19 Vaccines
18
mRna Vaccines general
14
Vector-based Vacines General
14
Moderna
13
Country specific documents
12
Communication Material
10
Immunization Guidelines
9
COVID-19 Vaccination
9
COVID-19 Vaccination Information
9
Scientific & Research Studies
8
Vaccine Candidates & Research
8
Johnson & Johnson
8
Dashboards & Resource Platforms
7
Logistics & Supply
6
Covaxin
6
For Migrants & Refugees
4
For Older People
4
Videos
4
SARS-CoV-2 Variants
4
Access & Strategy
3
Sputnik V
3
Anamnesis / Screening
2
Prevention & Preparedness
2
Training, others
2
For Health Worker
2
Booster Doses
2
Vaccination
1
Pediatrics
1
Clinical Guidelines
1
Clinical Aspects
1
Public Health
1
COVID-19 Information
1
For General Public & Community
1
For Parents & Children
1
Essential Medicines & Medical Devices
1
Vaccination & Strategy
1
Non-pharmaceutical interventions (NPIs)
1
Pharmacovigilance
1
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
Ausführliche Informationen zu klinischen Prüfungen und Risiken für bestimmte Gruppe sowie zu Wechselwirkungen und Nebenwirkungen.
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...
updated version: 04/10/2021
Information about vaccine administration
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc...
